How do the biologics fit into the current DMARD armamentarium?

Journal of Rheumatology

Volumn 28, Issue SUPPL. 62, 2001, Pages 27-35

  Kalden, J R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Biologicals; DMARD; Etanercept; Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR BLOCKER; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; AUTOIMMUNE DISEASE; DRUG ANTAGONISM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034987392     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Joint erosions and the patient with early rheumatoid arthritis
2. Survival, prognosis, and causes of death in rheumatoid arthritis
3. Work disability in early rheumatoid arthritis
4. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
5. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study
6. Long-term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rheumatoid arthritis (RA)
7. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate
8. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients
9. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
10. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
11. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
12. The role of tumor necrosis factor in health and disease
13. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
14. Inhibitors of tumor necrosis factor for rheumatoid arthritis
15. Influence of a recombinant human soluable tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice
16. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
17. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
18. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo
19. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
20. A Phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis (ENBREL ERA Trial)
21. Long term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Embrel) in DMARD refractory rheumatoid arthritis (RA)
22. Etanercept in children with polyarticular juvenile rheumatoid arthritis
23. Randomised double-blind comparison of chimeric monocloncal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
24. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
25. Therapeutic efficacy of multiple iv infusions of anti-tumor necrosis factor alpha monocloncal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
26. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
27. Chimeric anti-tumor necrosis factor-alpha monocloncal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
28. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
29. Targeted therapies in rheumatoid arthritis: The need for action
30. Current treatment strategies for rheumatoid arthritis
31. The impact of pharmaco-economic considerations on the utilization of novel antirheumatic therapies
32. Recapitulation of the round-table discussion-assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis
33. Building towards a consensus for the use of tumour necrosis factor blocking agents
34. Consensus statement on the initiation and continuation of tumor necrosis factor flocking therapies in rheumatoid arthritis